0	Alzheimer's disease	beta-amyloid (Abeta)	NA	ABSTRACT	Cerebrospinal fluid (CSF) 42 amino acid species of amyloid beta (Abeta42) and tau levels are strongly correlated with the presence of Alzheimer's disease (AD) neuropathology including amyloid plaques and neurodegeneration and have been successfully used as endophenotypes for genetic studies of AD.
0	Alzheimer's disease	NA	NA	ABSTRACT	Additional CSF analytes may also serve as useful endophenotypes that capture other aspects of AD pathophysiology.
0	NA	NA	NA	ABSTRACT	Here we have conducted a genome-wide association study of CSF levels of 59 AD-related analytes.
0	NA	NA	NA	ABSTRACT	All analytes were measured using the Rules Based Medicine Human DiscoveryMAP Panel, which includes analytes relevant to several disease-related processes.
0	Alzheimer's disease	NA	NA	ABSTRACT	Data from two independently collected and measured datasets, the Knight Alzheimer's Disease Research Center (ADRC) and Alzheimer's Disease Neuroimaging Initiative (ADNI), were analyzed separately, and combined results were obtained using meta-analysis.
0	NA	ACE	NA	ABSTRACT	We identified genetic associations with CSF levels of 5 proteins (Angiotensin-converting enzyme (ACE), Chemokine (C-C motif) ligand 2 (CCL2), Chemokine (C-C motif) ligand 4 (CCL4), Interleukin 6 receptor (IL6R) and Matrix metalloproteinase-3 (MMP3)) with study-wide significant p-values (p<1.46x10-10) and significant, consistent evidence for association in both the Knight ADRC and the ADNI samples.
0	NA	NA	NA	ABSTRACT	These proteins are involved in amyloid processing and pro-inflammatory signaling.
0	NA	ACE	NA	ABSTRACT	SNPs associated with ACE, IL6R and MMP3 protein levels are located within the coding regions of the corresponding structural gene.
0	NA	Chemokine (C-C motif) ligand 4	NA	ABSTRACT	The SNPs associated with CSF levels of CCL4 and CCL2 are located in known chemokine binding proteins.
0	NA	NA	NA	ABSTRACT	The genetic associations reported here are novel and suggest mechanisms for genetic control of CSF and plasma levels of these disease-related proteins.
0	Alzheimer's disease	ACE	NA	ABSTRACT	Significant SNPs in ACE and MMP3 also showed association with AD risk.
0	Alzheimer's disease	NA	NA	ABSTRACT	Our findings suggest that these proteins/pathways may be valuable therapeutic targets for AD.
0	NA	NA	NA	ABSTRACT	Robust associations in cognitively normal individuals suggest that these SNPs also influence regulation of these proteins more generally and may therefore be relevant to other diseases
0	Alzheimer's disease	NA	NA	ABSTRACT	The use of quantitative endophenotypes from cerebrospinal fluid has led to the identification of several genetic variants that alter risk or rate of progression of Alzheimer's disease.
0	NA	NA	NA	ABSTRACT	Here we have analyzed the levels of 58 disease-related proteins in the cerebrospinal fluid for association with millions of variants across the human genome.
0	NA	ACE	NA	ABSTRACT	We have identified significant, replicable associations with 5 analytes, Angiotensin-converting enzyme, Chemokine (C-C motif) ligand 2, Chemokine (C-C motif) ligand 4, Interleukin 6 receptor and Matrix metalloproteinase-3.
0	NA	NA	NA	ABSTRACT	Our results suggest that these variants play a regulatory role in the respective protein levels and are relevant to the inflammatory and amyloid processing pathways.
0	Alzheimer's disease	ACE	NA	ABSTRACT	Variants in associated with ACE and those associated with MMP3 levels also show association with risk for Alzheimer's disease in the expected directions.
0	Alzheimer's disease	NA	NA	ABSTRACT	These associations are consistent in cerebrospinal fluid and plasma and in samples with only cognitively normal individuals suggesting that they are relevant in the regulation of these protein levels beyond the context of Alzheimer's disease
0	aggressive disease	NA	NA	INTRO	Cerebrospinal fluid (CSF) contains promising biomarkers for neurological and psychiatric diseases such as Alzheimer's disease (AD), schizophrenia, and Parkinson's disease.
0	aggressive disease	NA	NA	INTRO	The brain directly and rapidly influences the composition of CSF, and as such, CSF analytes may provide insights into neurological and psychiatric disease pathways that may not be identifiable using blood or other biological fluids
0	Alzheimer's disease	NA	NA	INTRO	The use of endophenotypes in genome-wide association studies (GWAS) has provided novel insights into pathways and proteins that are associated with AD onset and progression.
0	Alzheimer's disease	beta-amyloid (Abeta)	NA	INTRO	We have demonstrated the utility of CSF amyloid-beta (Abeta), apolipoprotein E (ApoE) and tau levels as endophenotypes for genetic studies of AD.
0	NA	tau	NA	INTRO	In our most recent work we used nearly 1,300 samples to conduct a GWAS with CSF tau levels.
0	NA	NA	NA	INTRO	In that study, Cruchaga et al.
0	Alzheimer's disease	NA	rs9877502	INTRO	identified three genome-wide significant loci, including rs9877502, which also showed a consistent association with AD risk, tangle pathology, and global cognitive decline in independent datasets.
0	NA	NA	NA	INTRO	The success of these and other similar efforts has led to broader efforts to develop and leverage datasets of this type
0	Alzheimer's disease	NA	NA	INTRO	While amyloid plaques and neurofibrillary tangles are the primary pathological features of AD, genetic, clinical, and animal studies demonstrate that endocytosis, cholesterol metabolism, and inflammatory and immune responses also play an important roles in AD pathogenesis.
0	Alzheimer's disease	NA	NA	INTRO	To further leverage the advantages of the endophenotype based approach, we have sought to use analytes related to these other aspects of AD pathology.
0	NA	RBM	NA	INTRO	For this work we have obtained data from the Rules Based Medicine, Inc. (RBM) (Austin, TX) Human DiscoveryMAP Panel.
0	cancers	NA	NA	INTRO	This panel includes over 175 analytes selected from the constellation of known cytokines, chemokines, metabolic markers, hormones, growth factors, tissue remodeling proteins, angiogenesis markers, acute phase reactants, cancer markers, kidney damage markers, and central nervous system biomarkers.
0	Alzheimer's disease	NA	NA	INTRO	Analytes were quantitatively measured in CSF samples from 574 samples (including both cognitively normal and demented individuals) from two independent datasets to identify novel phenotypes that may contribute to the pathogenesis of AD.
0	NA	NA	NA	INTRO	After careful quality control and evaluation of the literature we selected 59 AD-related analytes for analysis in genome-wide association studies.
0	NA	ACE	NA	INTRO	We identified genome-wide significant associations between putatively functional SNPs and five phenotypes (Angiotensin-converting enzyme (ACE), Chemokine (C-C motif) ligand 2 (CCL2), Chemokine (C-C motif) ligand 4 (CCL4), Interleukin 6 receptor (IL6R) and Matrix metalloproteinase-3 (MMP3)).
0	Alzheimer's disease	NA	NA	INTRO	The genetic basis of variance in these important disease-related analytes may provide insights into the mechanisms contributing to AD and other human diseases
0	Alzheimer's disease	NA	NA	RESULTS	From the combined GWAS on 59 phenotypes with connections to AD in our literature search (table 1) and with 5.8M SNPs (table 1), we identified 335 SNPs associated with five CSF phenotypes where p<1.47x10-10 (Bonferroni correction for 342 million tests) and other filtering criteria (see Methods: Statistical Analysis) were met (Table S1).
0	NA	NA	NA	RESULTS	At least one study-wide significant marker was directly genotyped (not imputed) for each locus that showed association.
0	NA	NA	NA	RESULTS	While there were other genome-wide significant associations with several of the other 54 phenotypes, these signals did not meet the additional filtering criteria.
0	NA	NA	NA	RESULTS	At least one SNP met the study-wide significance level (1.46x10-10) for each of the five phenotypes discussed in detail below (Table 2).
0	NA	apolipoprotein E	NA	RESULTS	All associations were robust to adjustment for APOE epsilon4 genotype and CDR.
0	NA	NA	NA	RESULTS	In addition, all associations were qualitatively stable in clinical case/control strata as well as in strata approximating presence or absence of amyloid deposition based on CSF Abeta42 levels (Table 3).
0	NA	NA	NA	RESULTS	The most significant marker for each phenotype, all SNPs in the associated regions with putative function, and markers with previous records in the National Human Genome Research Institute (NHGRI) catalog of published genome-wide association studies (downloaded November 19th, 2013; http://www.genome.gov/gwastudies/) are listed in Table 2.
0	NA	NA	NA	RESULTS	P-values of all SNPs in the region surrounding each significant association are plotted in Figure 1.
0	NA	NA	NA	RESULTS	Manhattan plots for the five phenotypes can be found in supplementary figures S1-S5.
0	NA	NA	NA	RESULTS	Detailed descriptions of each gene can be found in Text S1
1	NA	ACE	rs4968782	FIG	A) region of rs4968782 (ACE), B) region of rs2228467 (CCL2), C) region of rs6808835 (CCL4), D) region of rs61812598 (IL6R), E) region of rs573521 (MMP3).
0	NA	NA	NA	FIG	The top SNP for each region is shown in purple.
0	NA	NA	NA	FIG	The correlations (r2) of each of the surrounding SNPs to the top SNP are shown in the indicated colors.
0	NA	NA	NA	FIG	Recombination rate is shown in blue.
0	NA	NA	NA	FIG	SNP annotation is as follows: circle = framestop, square-splice, diamond = nonsynonymous, triangle = coding, inverted triangle = UTR, X = conserved transcription factor binding, square with X = MCS44Placental, star = no annotation, circle with crosshairs = none
0	NA	Matrix metalloproteinase-3	NA	RESULTS	We observed a significant association between CSF MMP3 and CCL2 and gender, where both analytes were lower in females relative to males in cognitively normal samples from both ADNI and the Knight ADRC.
0	NA	Matrix metalloproteinase-3	NA	RESULTS	We also observed significantly increased MMP3 and CCL2 levels with increasing age in cognitively normal samples from both ADNI and the Knight ADRC.
0	NA	NA	NA	RESULTS	We failed to detect consistent association in both the ADNI and Knight ADRC samples with plasma levels of these analytes and age or gender.
0	NA	NA	NA	RESULTS	Full results including slopes of the regression models can be found in table S2 (CSF results) and table S3 (plasma results)
0	NA	ACE	NA	RESULTS	We identified seven SNPs significantly associated with ACE levels in CSF (Figure 1A).
0	NA	ACE	rs4968782	RESULTS	The minor allele of rs4968782 was associated with higher ACE CSF protein levels (p = 3.94x10-12) and explains 11% of the variance in CSF ACE levels.
0	NA	ACE	NA	RESULTS	The signal was consistent in cases/controls and in CSF Abeta42 strata defining presence/absence of Ass pathology and was also observed between this SNP and plasma ACE levels (p = 7.93x10-16).
0	NA	ACE	rs4343	RESULTS	A synonymous substitution in the ACE gene, rs4343 (rs4968782/rs4343: r2 = 0.93; D' = 1.0), was also associated with ACE levels in CSF and plasma (p = 3.71x10-8; p = 1.10x10-8, respectively).
0	NA	ACE	NA	RESULTS	CSF and plasma levels of ACE showed a significant and moderate correlation (Pearson's correlation coefficient = 0.28, p = 4.86x10-6).
0	NA	ACE	rs4316	RESULTS	Another synonymous substitution, rs4316 is also in high LD with these markers and shows significant association with CSF and plasma levels of ACE (see table 3).
0	NA	NA	rs4343	RESULTS	"Both rs4343 and rs4316 are predicted as ""likely to affect binding transcription factors"" by RegulomeDB."
0	NA	NA	NA	RESULTS	None of these SNPs remained significant after conditioning upon the others.
0	NA	ACE	NA	RESULTS	Rs4343 also appears in the NHGRI GWAS catalog associated with increased ACE activity levels in serum.
0	Alzheimer's disease	NA	NA	RESULTS	Association with AD status was observed (all four SNPs p<0.0075) in 17,008 AD cases and 37,154 controls from the International Genomics of Alzheimer's Project (IGAP) as described by Lambert et al and accessible at http://www.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php .
0	Alzheimer's disease	ACE	rs4968782	RESULTS	For each of the four ACE SNPs, rs4968782, rs4459609, rs4316 and rs4343, the same allele was associated with increased ACE levels and decreased risk for AD (table 3)
1	NA	chemokine binding protein-2	rs2228467	RESULTS	We identified one SNP, rs2228467, which results in a non-synonymous change (V41A) in the chemokine binding protein-2 (CCBP2) that is associated with increased CCL2 protein levels (CSF p = 3.71x10-18).
0	NA	CCL2	NA	RESULTS	This marker accounts for 13% of the variance in CSF CCL2 levels.
0	NA	NA	NA	RESULTS	Other SNPs in this region with moderate linkage disequilibrium (LD) also showed strong, but not study-wide significant, associations (Figure 1B).
0	NA	CCL2	rs2228467	RESULTS	The association of rs2228467 with CSF levels of CCL2 remained significant in cases/controls and in CSF Abeta42 strata defining presence/absence of Abeta pathology and was nominally associated with CCL2 levels in plasma (table 3).
0	NA	CCL2	NA	RESULTS	CSF and plasma CCL2 levels were significantly correlated (Pearson's correlation coefficient = 0.23, p = 1.93x10-4).
0	NA	NA	rs2228467	RESULTS	Both SIFT and PolyPhen2 predicted the rs2228467 V41A change to be damaging.
0	Alzheimer's disease	NA	rs2228467	RESULTS	The IGAP analysis failed to detect association between rs2228467 and risk for AD (table 3).
0	Alzheimer's disease	CCL2	NA	RESULTS	We failed to detect association between CSF CCL2 levels and AD status (p = 0.90).
0	NA	NA	NA	RESULTS	This SNP was not associated with other phenotypes in the NHGRI GWAS catalog
0	NA	Chemokine (C-C motif) ligand 4	NA	RESULTS	We identified 66 polymorphisms associated with CCL4 levels in CSF.
1	NA	Chemokine (C-C Motif) Receptor-Like 2	NA	RESULTS	This is a trans effect, all associated SNPs are located within a 187 kb region of chromosome 3 surrounding the Chemokine (C-C Motif) Receptor-Like 2 (CCRL2) gene (figure 1C).
1	NA	NA	rs6808835	RESULTS	The most significant association was observed with rs6808835 (p = 1.59x10-13).
1	NA	Chemokine (C-C Motif) Receptor-Like 2	rs6441977	RESULTS	A non-synonymous SNP in the CCRL2 gene, rs6441977 (rs6808835/rs6441977: r2 = 0.93; D' = 1.0), results in a V180M substitution and shows significant association with CSF CCL4 levels in the combined sample (p = 7.66x10-11) with CCL4 levels decreasing with each copy of the minor allele.
0	NA	Chemokine (C-C motif) ligand 4	NA	RESULTS	This SNP explains 10% of the variance in CSF CCL4 levels.
0	NA	NA	rs6762266	RESULTS	"Several significant, intergenic markers in this same region are predicted as ""likely to affect transcription factor binding and gene expression"" (rs6762266, rs11575821, rs11574428) and ""likely to affect transcription factor binding"" (rs113263161, rs3092960) using RegulomeDB."
0	NA	NA	NA	RESULTS	None of these SNPs remained significant after conditioning upon the others.
0	NA	beta-amyloid (Abeta)	NA	RESULTS	In addition to the association in the total dataset, this SNP shows consistent association in cases/controls, in CSF Abeta42 strata defining presence/absence of Abeta pathology and with CCL4 levels in plasma (table 3).
0	NA	Chemokine (C-C motif) ligand 4	NA	RESULTS	CSF and plasma levels of CCL4 were significantly correlated (Pearson's correlation coefficient = 0.37, p = 6.59x10-10).
0	NA	NA	NA	RESULTS	SIFT and PolyPhen 2 predicted the amino acid change to be benign.
0	Alzheimer's disease	Chemokine (C-C motif) ligand 4	NA	RESULTS	No SNPs associated with CCL4 showed significant association with AD in the IGAP analysis (table 3) and no significant SNPs were associated with other phenotypes in the NHGRI GWAS catalog
0	NA	Interleukin 6 receptor	NA	RESULTS	We identified 176 SNPs significantly associated with soluble IL6R (sIL6R) levels in CSF.
1	NA	TDRD12	NA	RESULTS	These significant SNPs were located in the region of chromosome 1 surrounding the TDRD12, SHE, and IL6R genes (figure 1D).
1	NA	NA	rs61812598	RESULTS	The most significant association was with rs61812598 (p = 5.9x10-62).
1	NA	Interleukin 6 receptor	rs2228145	RESULTS	Two non-synonymous SNPs were also associated with increased sIL6R protein levels in both CSF and plasma: rs2228145 (gene = IL6R, D358A, CSF p = 2.70x10-62, plasma p = 4.64x10-67) and rs3811448 (gene = TDRD10, V215I, CSF p = 3.36x10-15, plasma p = 7.91x10-12).
0	NA	NA	NA	RESULTS	CSF and plasma levels of sIL6R showed a significant correlation (Pearson's correlation coefficient = 0.49, p = 2.20x10-16).
1	NA	NA	rs2228145	RESULTS	In addition, rs2228145 exhibits nearly perfect LD with rs61812598 (r2 = 0.99; D' = 1.0).
1	NA	NA	rs3811448	RESULTS	Rs3811448 has a high D' with both rs2228145 (D' = 0.96) and rs61812598 (D' = 0.96) but its r2 with these SNPs is low (r2 = 0.15 with both SNPs).
1	NA	NA	rs4129267	RESULTS	"Another significant SNP in this region, rs4129267, has nearly complete LD with both rs61812598 and rs2228145 (D'>0.99, r2>0.99 in both cases), and is predicted by RegulomeDB as ""likely to affect transcription factor binding."""
0	NA	NA	NA	RESULTS	Tests conditioning on any of these SNPs results in no significant associations in this region.
1	NA	NA	rs2228145	RESULTS	Associations with both rs2228145 and rs61812598 (essentially the same test as they exhibit nearly perfect LD) remained genome-wide significant when conditioning upon rs3811448.
0	NA	NA	rs2228145	RESULTS	Rs2228145 accounts for about 40% of variance in CSF sIL6R levels.
0	NA	NA	NA	RESULTS	Neither amino acid change is predicted to affect its respective protein's function by SIFT or Polyphen 2.
0	Alzheimer's disease	NA	NA	RESULTS	The IGAP analysis failed to detect association between the markers associated with sIL6R and AD risk (table 3).
0	asthma	C-reactive protein	rs4129267	RESULTS	We found significant SNPs in our analyses that have been previously reported to be associated with asthma, C-reactive protein levels (rs4129267), and coronary heart disease (rs2229238) in the NHGRI GWAS catalog
0	NA	Matrix metalloproteinase-3	NA	RESULTS	Eighty-five SNPs were significantly associated with MMP3 levels (figure 1E).
1	NA	NA	rs573521	RESULTS	The most significant association was observed with rs573521 (p = 2.39x10-44).
1	NA	Matrix metalloproteinase-3	rs679620	RESULTS	A non-synonymous mutation in MMP3, rs679620 (K45E), shows high LD with rs573521 (r2 = 0.99; D' = 1.0).
0	NA	NA	NA	RESULTS	Neither of these two SNPs remained significant after conditioning upon the other.
0	NA	Matrix metalloproteinase-3	rs679620	RESULTS	Rs679620 was also significantly associated with MMP3 levels in CSF (p = 4.93x10-44) with MMP3 levels increasing with each copy of the minor allele.
0	NA	Matrix metalloproteinase-3	NA	RESULTS	This SNP accounts for about 30% of the variance in CSF MMP3 levels.
0	NA	beta-amyloid (Abeta)	NA	RESULTS	Association of this marker is consistent in cases/controls and in CSF Abeta42 strata defining presence/absence of Abeta pathology and was also observed nominally with plasma MMP3 levels (table 3).
0	NA	Matrix metalloproteinase-3	NA	RESULTS	CSF and plasma MMP3 levels were moderately and significantly correlated (Pearson's correlation coefficient = 0.33, p = 2.06x10-5).
0	NA	NA	rs679620	RESULTS	SIFT and PolyPhen 2 predicted the rs679620 K45E amino acid change to be benign.
0	NA	NA	Rs948399	RESULTS	"Rs948399 also showed significant association and was predicted by RegulomeDB as ""likely to affect transcription factor binding."""
1	Alzheimer's disease	NA	rs573521	RESULTS	Three SNPs, rs573521, rs645419 and rs679620 showed nominal significance in the IGAP AD association analysis (table 3).
0	NA	MMP1	rs7926920	RESULTS	From the NHGRI GWAS catalog, five SNPs previously reported to be associated with MMP1 levels in plasma in a recent genome-wide association study (rs7926920, rs11225434, rs495366, rs603050, and rs650108) are also significantly associated with MMP3 levels in CSF in our data.
0	NA	Matrix metalloproteinase-3	NA	RESULTS	MMP3 and MMP1 are located in the same region on chromosome 11 and show strong correlation in their pattern of expression suggesting that there may be coordinated regulation of these two genes.
1	NA	Matrix metalloproteinase-3	rs573521	RESULTS	These SNPs are located in the 37 kb region between MMP3 and MMP1 and show high LD (D'~1) with rs573521 and rs679620
0	NA	NA	NA	RESULTS	We used Multiphen, to perform a multivariate test of the linear combination of phenotypes most associated with the genotypes at each of our top SNPs.
0	NA	NA	NA	RESULTS	At least one marker from each of the loci in our top hits showed genome-wide significance in the joint models (Table 4).
0	NA	prolactin	NA	RESULTS	Several SNPs showed strong association with sIL6R and prolactin (PRL).
0	NA	CCL2	rs2228467	RESULTS	Rs2228467, which showed primary association with CCL2, also showed association with glutamic-oxaloacetic transaminase 1 (GOT1).
0	NA	NA	NA	RESULTS	Full results including p-values and metaanalysis of each of the top SNPs with each phenotype are provided in Table S4
0	NA	NA	NA	DISCUSS	We have identified loci significantly associated with levels of five AD-related CSF analytes.
0	NA	ACE	NA	DISCUSS	Our findings include cis effects (defined as SNPs within 5 kb on either side of the transcribed gene) for ACE, sIL6R and MMP3 levels and trans effects for CCL2 and CCL4 levels.
0	NA	ACE	NA	DISCUSS	For each of the loci except ACE, a non-synonymous SNP is among the most strongly associated variants.
0	NA	NA	NA	DISCUSS	SNPs in all five loci were associated with each of the analytes even after a highly conservative multiple test correction (alpha = 1.46x10-10).
0	Alzheimer's disease	NA	NA	DISCUSS	All results are consistent when analyses are stratified by clinical status and when stratified by CSF Abeta42 levels that are indicative of AD pathology, suggesting that these results are relevant in normal conditions, not just in the context of AD.
0	NA	NA	NA	DISCUSS	In addition, all of the associated SNPs showed association with their respective plasma analytes, further supporting the robustness of the genetic associations.
0	NA	ACE	NA	DISCUSS	The ACE, MMP3 and CCL2 proteins have been previously described to have an impact on amyloid beta processing.
0	NA	NA	NA	DISCUSS	The remaining proteins are involved in the pro-inflammatory response.
0	NA	NA	NA	DISCUSS	The results of our Multiphen analysis did not provide strong evidence that these SNPs regulate expression of multiple traits in similar pathways
0	Alzheimer's disease	ACE	NA	DISCUSS	Angiotensin converting enzyme (ACE) is encoded by the ACE gene (17q23.3) and has been previously implicated in AD pathogenesis.
0	familial aggregation	ACE	NA	DISCUSS	In vitro, ACE inhibits Abeta aggregation in an activity-dependent manner by slowing the rate of fibril formation.
0	familial aggregation	ACE	NA	DISCUSS	ACE may inhibit Abeta aggregation by converting the highly amyloidogenic Abeta42 peptide into the more stable Abeta40 peptide.
0	Alzheimer's disease	ACE	NA	DISCUSS	In vivo, inhibition of ACE activity in an AD mouse model promotes Abeta42 deposition in the hippocampus.
0	NA	ACE	NA	DISCUSS	Studies in mouse and human brain homogenate demonstrate that ACE causes Abeta degradation in a two-step process.
0	NA	ACE	NA	DISCUSS	First, ACE cleaves Abeta42 into Abeta40 and then Abeta40 undergoes degradation
0	Alzheimer's disease	ACE	NA	DISCUSS	ACE activity is elevated in the CSF of AD patients.
0	neuroblastoma	ACE	NA	DISCUSS	Neuroblastoma cells exposed to synthetic Abeta42 oligomers, but not monomeric Abeta42, produce elevated ACE protein levels and ACE activity, suggesting that Abeta aggregates may stimulate the up-regulation of ACE in AD brains as a mechanism of combatting the accumulation of these protein aggregates
0	NA	ACE	NA	DISCUSS	Our findings suggest that SNPs within the ACE locus alter CSF and plasma ACE levels.
0	NA	ACE	NA	DISCUSS	Several SNPs in the ACE gene region have significant associations with increased levels of ACE.
0	NA	NA	NA	DISCUSS	Conditional analyses suggest a single signal in this region is responsible for the association.
0	NA	NA	rs4343	DISCUSS	While we are unable to determine the specific functional allele in this region, rs4343 and rs4316 are in nearly perfect LD with each other (D' = 0.99, r2 = 0.91) and both are inferred to have regulatory function (table 3).
0	Alzheimer's disease	NA	NA	DISCUSS	Rs4316 has not been studied in AD or reported to be associated with other phenotypes to date.
0	NA	ACE	NA	DISCUSS	Rs4343 is a widely studied marker in ACE, and we found a significant association of this SNP with increased CSF ACE levels.
0	NA	ACE	rs4343	DISCUSS	"The minor allele ""G"" of rs4343 has been previously reported to be significantly associated with increased plasma ACE activity levels and plasma ACE protein levels."
0	NA	ACE	rs4343	DISCUSS	Our observation of increased CSF ACE levels with the G allele of rs4343 is consistent with these reports
0	Alzheimer's disease	NA	rs4343	DISCUSS	In relation to AD, the findings with rs4343 have been varied with some studies suggesting association with CSF Abeta42 levels and AD risk while others do not.
0	NA	tau	NA	DISCUSS	Recent data from 1269 samples with CSF and genetic data failed to detect association between CSF Abeta42, Tau or pTau181 levels and these SNPs in ACE (table 3).
0	Alzheimer's disease	ACE	NA	DISCUSS	Results from the recent International Genomics of Alzheimer's Project provide evidence of association between the SNPs in ACE we report to be associated with higher CSF ACE levels and reduced risk for AD.
0	Alzheimer's disease	ACE	NA	DISCUSS	In addition, recent work using 600 samples with CSF ACE measurements found a significant increase in ACE levels with increasing ptau/Abeta42 ratio (which was used as a predictor of AD status), further reinforcing the relationship between ACE levels and AD status
0	Alzheimer's disease	ACE	NA	DISCUSS	Our results demonstrate in human subjects that SNPs in the ACE gene are associated with elevated CSF and plasma ACE protein levels and that these SNPs are also associated with reduced AD risk.
0	Alzheimer's disease	ACE	NA	DISCUSS	Taken with in vitro and in vivo studies that demonstrate that ACE cleaves and clears Abeta in an activity-dependent manner, these findings suggest that individuals carrying polymorphisms that increase ACE protein, and possibly ACE activity, may be better able to clear accumulating Abeta aggregates and are thus at reduced risk for developing AD
0	NA	Matrix metalloproteinase-3	NA	DISCUSS	Matrix metalloproteinase 3 (encoded by MMP3; located on 11q22.3) is hypothesized to contribute to endogenous, physiologic clearance of amyloid plaques.
0	NA	Matrix metalloproteinase-3	NA	DISCUSS	MMP3 is expressed in neurons, astrocytes, microglia and vascular cells.
0	Alzheimer's disease	Matrix metalloproteinase-3	NA	DISCUSS	MMP3 is preferentially localized in senile plaques in the parietal cortex of AD brains, while hippocampal plaques are relatively spared of MMP3.
0	NA	beta-amyloid (Abeta)	NA	DISCUSS	Abeta treatment causes upregulation of MMP3 expression in primary astrocyte cultures and in mixed hippocampal cultures.
0	NA	Matrix metalloproteinase-3	NA	DISCUSS	MMP3 also degrades extracellular Abeta.
0	Alzheimer's disease	MMP2	NA	DISCUSS	The closely related MMP2 and MMP9 proteins have been well studied in the context of AD pathogenesis.
0	Alzheimer's disease	MMP2	NA	DISCUSS	Astrocytes that surround plaques in AD mouse brains show enhanced MMP2 and MMP9 expression.
0	NA	beta-amyloid precursor protein	NA	DISCUSS	Conditioned astrocyte media is sufficient to reduce synthetic Abeta levels, which is abolished with treatment of inhibitors specific to MMP2 and MMP9.
0	NA	MMP9	NA	DISCUSS	MMP9 can degrade fibrillar Abeta in vitro and plaques in hippocampal slice cultures.
0	Alzheimer's disease	MMP2	NA	DISCUSS	In an AD mouse model, knocking out MMP2 and MMP9 results in increased steady-state Abeta.
0	NA	beta-amyloid precursor protein	NA	DISCUSS	Thus, MMP proteins may contribute to Abeta clearance by promoting Abeta catabolism
0	Alzheimer's disease	Matrix metalloproteinase-3	NA	DISCUSS	Supporting the relationship of MMP3 with Alzheimer's disease, CSF MMP3 levels are increased in individuals with a ptau181/Abeta42 ratio indicative of AD.
0	NA	tau	NA	DISCUSS	In a previous study, we failed to detect an association between significant SNPs in this study and CSF Abeta42, Tau or pTau181 levels (table 3).
0	Alzheimer's disease	Matrix metalloproteinase-3	NA	DISCUSS	Studies testing the association of MMP3 SNPs and haplotypes and risk for AD have produced mixed results.
0	NA	NA	rs679620	DISCUSS	There appears to be two tiers of association in this locus, one group of SNPs with p-values less than 1E-38, which includes the non-synonymous SNP rs679620, and another which p-values between 1E-08 and 1E-12, including several variants with inferred regulatory function.
0	NA	NA	NA	DISCUSS	Conditional analyses of our data in this region indicate that the more strongly associated group of variants tags a single association signal and that no independent associations are detected in this region.
0	NA	Matrix metalloproteinase-3	rs679620	DISCUSS	While we cannot definitively identify the causal variant, rs679620, a non-synonymous SNP in the MMP3 region, was significantly associated with increased CSF MMP3 levels.
0	Alzheimer's disease	NA	NA	DISCUSS	This suggests a possible protective effect of this variant with respect to AD.
1	Alzheimer's disease	Matrix metalloproteinase-3	rs573521	DISCUSS	We found that rs573521, rs645419 and rs679620 are associated with increased CSF MMP3 levels in this study and with reduced risk of AD in the IGAP study.
0	Alzheimer's disease	Matrix metalloproteinase-3	NA	DISCUSS	These associations provide additional support for the role of MMP3 in AD pathology.
0	NA	Matrix metalloproteinase-3	NA	DISCUSS	In addition, the identification of SNPs in the intergenic region between MMP3 and MMP1 that are associated with both MMP3 and MMP1 levels suggest a common regulatory locus or close functional relationship between these members of the MMP gene family.
0	Alzheimer's disease	Matrix metalloproteinase-3	NA	DISCUSS	The identification of SNPs near MMP3 that are associated with increased CSF MMP3 protein levels and reduced AD risk supports the protective role of MMP3 in clearing Abeta from human brains
0	NA	CCL2	NA	DISCUSS	CCL2, also called monocyte chemotactic protein-1 or MCP-1, is encoded by the CCL2 gene, located on chromosome 17q11.2-q12.
0	NA	NA	NA	DISCUSS	It is a chemokine that is involved in immunoregulatory and pro-inflammatory processes.
0	Alzheimer's disease	CCL2	NA	DISCUSS	Amyloid plaques in AD brains are surrounded by activated immune cells that produce CCL2 among other chemokines.
0	Alzheimer's disease	CCL2	NA	DISCUSS	In the absence of CCL2, amyloid pathology is accelerated in an AD mouse model, illustrating its important role in amyloid plaque clearance and pointing to a potentially reparative role in AD.
0	Alzheimer's disease	CCL2	NA	DISCUSS	However, overexpression of CCL2 in an AD mouse model resulted in marked accumulation of reactive microglia and enhanced diffuse plaque accumulation, suggesting a role in Abeta aggregation.
0	toxicity	CCL2	NA	DISCUSS	In vitro work suggests that inhibition of CCL2 synthesis, reduces Abeta25-35- and Abeta1-42-induced toxicity in primary neuronal cultures.
0	NA	CCL2	NA	DISCUSS	Interestingly, treatment of primary astrocyte cultures with synthetic Abeta42 causes astrocytes to increase CCL2 synthesis and release and astrocyte migration in response to CCL2 is reduced in the presence of Abeta42.
0	Alzheimer's disease	CCL2	NA	DISCUSS	Thus, Abeta42 in AD brains may stimulate astrocyte-mediated CCL2 release and result in increased neuronal susceptibility to Abeta42 toxicity.
0	Alzheimer's disease	CCL2	NA	DISCUSS	The immune system involves a delicate and perfectly coordinated balance to function well; so, it is conceivable that CCL2 could play reparative and deleterious roles in AD pathogenesis
0	cognitive defects	CCL2	NA	DISCUSS	A 2006 study evaluated CCL2 levels in serum samples from 48 individuals with Mild Cognitive Impairment (MCI), 94 AD patients and 24 age-matched controls.
0	Alzheimer's disease	CCL2	NA	DISCUSS	Significantly increased plasma CCL2 levels were found in MCI and mild AD, but not in severe AD patients, as compared with controls.
0	Alzheimer's disease	CCL2	NA	DISCUSS	It has also been reported that increased CSF CCL2 levels at baseline in patients with prodromal AD correlated with a faster cognitive decline during the study's follow-up period.
0	Alzheimer's disease	CCL2	NA	DISCUSS	The largest study to date examined 600 samples with CSF CCL2 measurements and observed a significant increase in CCL2 protein levels with ptau/Abeta42 ratio indicative of AD.
0	Alzheimer's disease	NA	NA	DISCUSS	As is the case with most pro-inflammatory cytokines and cytokine receptors, the levels increase in AD cases
1	NA	chemokine binding protein-2	rs2228467	DISCUSS	Rs2228467, located within the CCBP2 gene, is significantly associated with increased CSF CCL2 protein levels.
1	NA	chemokine binding protein-2	NA	DISCUSS	The CCBP2 gene encodes the chemokine-binding protein 2 and demonstrates a high affinity for binding to CCL2.
0	NA	NA	NA	DISCUSS	Conditional analyses suggest that this marker accounts for the entirety of the association signal in this region.
0	NA	NA	NA	DISCUSS	Previous studies suggest that chemokine receptors can demonstrate high affinity binding to chemotactic proteins; however, how polymorphisms in one chemokine affect expression and function of associated chemokines is poorly understood.
0	NA	NA	NA	DISCUSS	PolyPhen2 and SIFT both predicted this amino acid change to be damaging.
0	NA	NA	rs2228467	DISCUSS	A recent study found that rs2228467 is significantly associated with lower circulating monocyte counts in the blood (p = 1.57x10-7).
1	NA	chemokine binding protein-2	rs2228467	DISCUSS	If the rs2228467 polymorphism affects the chemokine function of CCBP2 or CCL2, then this could have downstream effects on the recruitment of macrophages and dendritic cells and, in turn, monocyte development
0	NA	CCL2	NA	DISCUSS	CCL2 is known to be a necessary component in monocytes crossing the blood brain barrier.
0	NA	CCL2	rs2228467	DISCUSS	Our findings suggest that increased CCL2 associated with variation at rs2228467 may cause a chemotactic response that results in lower levels of circulating monocytes in the blood.
0	Alzheimer's disease	CCL2	rs2228467	DISCUSS	While rs2228467 has strong effects on CCL2 levels and CSF CCL2 levels change in Alzheimer's disease, this SNP does not appear to impact risk for AD or CSF Abeta42 levels (p = 0.45).
0	psoriasis	CCL2	rs2228467	DISCUSS	However, as CCL2 has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis further investigation of rs2228467 with regard to these and related diseases is clearly warranted
1	NA	chemokine binding protein-2	NA	DISCUSS	Here we have demonstrated in human subjects that SNPs in the CCBP2 gene are significantly associated with elevated CSF CCL2 protein levels.
0	Alzheimer's disease	CCL2	NA	DISCUSS	While, CSF CCL2 protein levels are not significantly associated with AD risk, evidence in mouse and cell models of AD suggest that increasing CCL2 levels increases microgliosis, amyloid plaque accumulation, and neuronal toxicity associated with Abeta.
0	Alzheimer's disease	CCBP2	NA	DISCUSS	Taken together, these findings implicate CCBP2 and CCL2 as risk factors for AD pathogenesis
0	NA	Chemokine (C-C motif) ligand 4	NA	DISCUSS	The CCL4 protein is encoded by the CCL4 gene (17q12).
0	Alzheimer's disease	Chemokine (C-C motif) ligand 4	NA	DISCUSS	Studies evaluating the relationship between AD and inflammation have shown that CCL4 is expressed in subpopulations of reactive astrocytes and in microglia.
0	Alzheimer's disease	beta-amyloid (Abeta)	NA	DISCUSS	Neuritic plaques in AD are surrounded by activated microglia and astrocytes, which may produce inflammatory products when stimulated with Abeta.
0	NA	Chemokine (C-C motif) ligand 4	NA	DISCUSS	Macrophages showed an increased secretion of CCL4 when treated with Abeta.
0	NA	Chemokine (C-C motif) ligand 4	NA	DISCUSS	Current information concerning CCL4 and other plaque-associated chemokines suggests that their production plays a role in the recruitment and accumulation of astrocytes and microglia in senile plaques.
0	Alzheimer's disease	Chemokine (C-C motif) ligand 4	NA	DISCUSS	These data suggest a possible relationship between CCL4 and AD pathogenesis
0	NA	Chemokine (C-C motif) ligand 4	NA	DISCUSS	We identified association between several SNPs, including one non-synonymous SNP, one synonymous SNP and five markers with predicted regulatory effects, and CSF CCL4 levels.
0	NA	NA	NA	DISCUSS	Conditional analyses suggest that these SNPs tag a single association signal in this region.
0	Alzheimer's disease	tau	NA	DISCUSS	These SNPs do not show association with AD in the IGAP dataset or with CSF Abeta42, Tau or pTau181 levels (table 3).
0	Alzheimer's disease	Chemokine (C-C motif) ligand 4	NA	DISCUSS	In addition, CSF CCL4 levels are not significantly associated with ptau181/Abeta42 ratio, a predictor of AD status.
0	Alzheimer's disease	Chemokine (C-C motif) ligand 4	NA	DISCUSS	These results do not indicate a role for CCL4 levels in risk for AD.
0	AIDS	Chemokine (C-C motif) ligand 4	NA	DISCUSS	However, CCL4 may play a role in HIV Type 1 transmission, AIDS disease progression, and acute kidney injury.
1	NA	Chemokine (C-C Motif) Receptor-Like 2	rs6441977	DISCUSS	Thus it will be important to evaluate the impact of rs6441977 (V168M polymorphism in CCRL2; associated with decreased CCL4 levels) and other markers with regulatory effects, on these and related diseases
0	NA	Interleukin 6 receptor	NA	DISCUSS	The interleukin 6 receptor (IL6R) is a protein encoded by the IL6R gene (1q21).
0	NA	IL-6	NA	DISCUSS	Interleukin 6 is a potent pleiotropic pro-inflammatory cytokine that regulates cell growth and differentiation and plays an important role in the immune response and may also play a role in hippocampal neurogenesis
0	NA	Interleukin 6 receptor	NA	DISCUSS	We identified association with sIL6R levels for several SNPs in the IL6R region.
1	NA	NA	rs61812598	DISCUSS	Conditional analyses suggest that this is a single signal is driven by rs61812598 and other SNPs in high LD with these markers.
0	NA	NA	rs2228145	DISCUSS	Among these, rs2228145, rs3811448 and rs4129267 have predicted functional effects (see table 3).
1	NA	NA	rs3811448	DISCUSS	Rs3811448, a non-synonymous marker in the associated region is not significant when conditioning upon rs61812598, rs4129267 or rs2228145.
1	NA	NA	rs61812598	DISCUSS	Conversely, both rs61812598 rs4129267 and rs2228145 remain highly significant upon conditioning for rs3811448.
1	NA	NA	rs61812598	DISCUSS	This makes it clear that there is a single signal in this region, tagged by rs61812598, rs4129267 and rs2228145, which are in complete LD with each other
0	NA	Interleukin 6 receptor	rs2228145	DISCUSS	Rs2228145 is a non-synonymous polymorphism in the IL6R gene, (D358A).
0	NA	NA	rs2228145	DISCUSS	While both SIFT and Polyphen 2 predict this change to be benign, rs2228145 has recently been shown to significantly increase plasma concentrations of sIL-6R, and reduce concentrations of membrane-bound IL-6R, resulting in impaired IL-6 responsiveness.
0	NA	Interleukin 6 receptor	rs2228145	DISCUSS	These results demonstrate that consequential changes in protein levels, likely resulting from the rs2228145 polymorphism, may translate into a functional impairment in IL-6R signaling.
0	NA	NA	rs2228145	DISCUSS	The rs2228145 polymorphism and other SNPs in this region have previously been shown to be significantly associated with plasma sIL-6 levels Trans-signaling is important for IL6-mediated cellular communication with molecular targets and that blocking trans-signaling lessen the deleterious effects of IL6 signaling.
0	NA	Interleukin 6 receptor	NA	DISCUSS	Trans-signaling occurs via sIL6R, which is the proteolyzed product of IL6R.
0	NA	Interleukin 6 receptor	NA	DISCUSS	IL6R is proteolyzed by gamma-secretase, which also cleaves APP.
0	Alzheimer's disease	Interleukin 6 receptor	NA	DISCUSS	Thus, polymorphisms in IL6R that modify IL6 signaling may result in modulation of signaling to many downstream targets that directly or indirectly influence AD pathogenesis
0	Alzheimer's disease	apolipoprotein E	rs2228145	DISCUSS	Additionally, rs2228145 has been implicated previously as significantly increasing the risk of sporadic AD in a Chinese Han population in subjects without the APOE epsilon4 allele.
0	Alzheimer's disease	NA	NA	DISCUSS	While sIL6R levels have been previously reported to decrease in AD cases, a recent study using a much larger sample found a significant increase in CSF sIL6R levels and increasing ptau181/Abeta42 ratio, suggesting a possible relationship between sIL6R levels and AD pathogenesis
0	NA	IL-6	NA	DISCUSS	It has been proposed that there is a reciprocal relationship between IL-6 and Abeta.
0	NA	NA	NA	DISCUSS	The IL-6/sIL-6R complex is reported to enhance APP transcription and expression.
0	Alzheimer's disease	NA	rs2228145	DISCUSS	Based on these data, rs2228145, which is associated with increased sIL6R levels, would be predicted to alter CSF Abeta42 levels and risk for AD.
0	Alzheimer's disease	Interleukin 6 receptor	NA	DISCUSS	Unfortunately, we did not detect association of markers in IL6R with AD risk in the IGAP analysis and association with AD biomarkers was weak and inconsistent (table 3)
0	NA	Interleukin 6 receptor	rs4129267	DISCUSS	Rs4129267 is located within the intronic region of IL6R.
0	NA	Olf-1	NA	DISCUSS	"This SNP is inferred to be ""likely to affect binding"" of the Olf-1 transcription factor using RegulomeDB."
0	NA	NA	rs2228145	DISCUSS	Like rs2228145, this marker is associated with sIL6R levels.
0	asthma	fibrinogen	NA	DISCUSS	In addition, this marker has been reported to be associated with levels of fibrinogen and C-reactive protein in blood as well as asthma and pulmonary function.
0	NA	NA	rs2228145	DISCUSS	While it remains unclear what the causal marker is for this association signal due to the high levels of LD, the putative functional effects of both rs2228145 and rs4129267 make them top candidates for future investigation
0	multiple myeloma	IL-6	NA	DISCUSS	Dysregulated production of IL6 and its receptor are implicated in the pathogenesis of many diseases, including multiple myeloma, autoimmune diseases, and prostate cancer.
0	asthma	C-reactive protein	NA	DISCUSS	In addition, the association of several significant SNPs in our study with asthma, C-reactive protein levels and coronary heart disease highlights the relationship between the inflammatory response and these disorders.
0	NA	NA	rs2228145	DISCUSS	This information suggests a central role for the IL6/sIL6R complex in these and possibly other diseases and suggests that further characterization of the effects of rs2228145 and rs4129267 on human disease phenotypes is warranted
0	NA	NA	NA	DISCUSS	In conclusion, we have identified significantly associated SNPs for five different AD-related analytes.
0	dementia	NA	NA	DISCUSS	These associations are robust across different biological fluids, dementia status and inferred presence of AD pathology both within and between independent sample sets.
0	Alzheimer's disease	ACE	NA	DISCUSS	The SNPs observed to be associated with CSF ACE and MMP3 levels also appear to show association with AD in the predicted direction, providing support for previous hypotheses of involvement of these genes and their function in amyloid clearance for risk for AD.
0	Inflammation Laboratory's JDRF	NA	NA	DISCUSS	While inflammation is known to play an important role in AD, the pro-inflammatory markers investigated here, and their associated SNPs, do not appear to alter AD risk or disease progression.
0	Alzheimer's disease	NA	NA	DISCUSS	However, because the immune system is an exceedingly complex set of signaling cascades that must be perfectly regulated in order to function properly and because this regulation involves constant flux, we may not be able to fully capture the subtle effects in the function of these proteins that have a cumulative effect on AD pathogenesis over the course of a lifetime.
0	NA	NA	NA	DISCUSS	The reproducibility of our findings in cognitively normal individuals and in plasma levels of the respective proteins as well as putative functional effects of these variants suggest that these SNPs may directly affect their respective proteins.
0	NA	NA	NA	DISCUSS	Thus, insights into the genetic basis of variance in important pro-inflammatory protein levels are relevant to other diseases that are modulated by those processes.
0	NA	NA	NA	DISCUSS	Finally, our findings demonstrate the continued utility of an endophenotype-based approach to finding functional alleles and disease-associated loci
0	NA	NA	NA	METHODS	Data used in the preparation of this article were obtained from the ADNI database (www.loni.ucla.edu\ADNI).
0	NA	NA	NA	METHODS	CSF was collected as described previously.
0	NA	NA	NA	METHODS	Genetic and phenotypic data for 308 samples was available for this study.
0	NA	NA	NA	METHODS	Demographics of the samples included in this manuscript are reported in Table 5
0	NA	NA	NA	METHODS	CSF samples from 266 individuals from the Knight-Alzheimer's disease Research Center at Washington University School of Medicine (Knight ADRC) were used in this study.
0	NA	NA	NA	METHODS	A detailed description of these samples and CSF collection methods has been published previously.
0	NA	NA	NA	METHODS	Demographics of these samples are described in Table 5
0	NA	NA	NA	METHODS	CSF and plasma samples from the Knight ADRC were evaluated for levels of 190 analytes using the Human DiscoveryMAP Panel and a Luminex 100 platform.
0	NA	NA	NA	METHODS	CSF and plasma samples from the ADNI sample were assessed using the same Human DiscoveryMAP Panel and measurement platform.
0	NA	NA	NA	METHODS	After filtering each set independently for phenotypes that had valid measurements in at least 90% of the samples, the intersection resulted in 76 analytes.
0	NA	NA	NA	METHODS	For each of the 76 analytes that passed quality assurance in both datasets we performed a PubMed search on August 11, 2013.
0	Alzheimer's disease	NA	NA	METHODS	The purpose of this literature search was to reduce the phenotype list to those that are relevant to our AD centered samples from the Knight ADRC and ADNI, thus reducing the dimensionality of the data and concentrating statistical power on the most relevant phenotypes.
0	Alzheimer's disease	NA	NA	METHODS	"Search terms included any of the following three terms, the name of the analyte on the chip, the official gene name and the official protein name and the term ""Alzheimer's disease""."
0	NA	NA	NA	METHODS	"Analytes with more than 50 search results are considered to be ""AD-related""."
0	Alzheimer's disease	NA	NA	METHODS	For analytes with fewer than 50 search results we inspected the manuscripts manually to determine whether there was evidence for a relationship with AD.
0	NA	NA	NA	METHODS	A list of all analyte names on the chip along with official gene and protein names and results of the literature search is provided in supplementary Table S5
0	NA	NA	NA	METHODS	All samples were genotyped using the Illumina 610 or the Omniexpress chip.
0	NA	NA	NA	METHODS	Prior to statistical analysis, sample data were filtered using rigid quality control (QC) criteria by array: minimum call rate (98%), minimum minor allele frequency (2%), and exclusion of SNPs out of Hardy-Weinberg equilibrium (p<1x10-6).
0	NA	NA	NA	METHODS	Unanticipated duplicates and related individuals were prioritized after calculating pairwise genome-wide estimates of identity-by-descent.
0	NA	NA	NA	METHODS	Eigensoft was used to calculate principal component factors for each sample and confirm ethnicity.
0	NA	NA	NA	METHODS	These calculations were included as covariates in our analysis to adjust for possible confounding effects of population stratification
0	NA	NA	NA	METHODS	The 1000 genome data (June 2012 release) and the Beagle software were used to impute genotypes in the combined ADNI and Knight ADRC samples.
0	NA	NA	NA	METHODS	SNPs with a Beagle r2 of 0.3 or lower, a minor allele frequency (MAF) lower than 0.05, out of Hardy-Weinberg equilibrium (p<1x10-6), a call rate lower than 95% or a Gprobs score lower than 0.90 were removed.
0	NA	NA	NA	METHODS	A total of 5,815,690 SNPs passed the QC process
0	NA	NA	NA	METHODS	The Kolmogorov-Smirnov goodness-of-fit test was performed to evaluate normality of the 59 phenotypes of interest in the Knight ADRC samples.
0	NA	NA	NA	METHODS	When deviations were observed, phenotypes were log transformed to approximate a normal distribution.
0	NA	NA	NA	METHODS	The ADNI data for these samples and phenotypes had already been adjusted to fit normal distribution patterns by the ADNI biomarker core.
0	dementia	NA	NA	METHODS	Associations reported for age and gender were performed in cognitively normal samples only to reduce potential confounds of dementia
0	NA	NA	NA	METHODS	We performed a genome-wide association for each of the 59 phenotypes to identify genetic loci associated with protein levels in CSF.
0	NA	NA	NA	METHODS	For the initial association analysis in each series we used PLINK to perform linear regression and evaluated the association between the additive model for 5.8M SNPs and each phenotype.
0	NA	NA	NA	METHODS	Age, gender, and the principal components from Eigensoft analysis were included as covariates.
0	NA	NA	NA	METHODS	Variance explained by each marker is reported as the difference in the model r2 between full models with and without the SNP included as a variable.
0	NA	NA	NA	METHODS	Association of SNPs of interest with plasma analyte levels in the ADNI and Knight ADRC samples was calculated using the same approach.
0	NA	NA	NA	METHODS	Analysis of each sample separately reduces the possible confound of demographic or ascertainment differences between the ADNI and Knight ADRC samples
0	NA	NA	NA	METHODS	Genome-wide association results from the two datasets were meta-analyzed using the default settings in METAL.
0	NA	GIF	NA	METHODS	Genomic inflation factor scores (GIF) were estimated using the R package GenABEL.
0	NA	NA	NA	METHODS	We set a strict and extremely conservative study-wide alpha level of 1.46x10-10 for the combined analysis.
0	NA	NA	NA	METHODS	This was calculated by applying a Bonferroni correction for 5.8 million SNPs and 59 analytes, or 342.2 million tests.
0	NA	NA	NA	METHODS	SNPs that met the initial significance criteria were further filtered using the following criteria.
0	NA	NA	NA	METHODS	First, we rejected SNPs where the direction of the effect was different in the Knight ADRC and ADNI datasets.
0	NA	NA	NA	METHODS	Second, we removed all SNPs where the minor allele frequency was less than 5% (unless they were directly genotyped).
0	NA	GIF	NA	METHODS	Finally, we rejected all associations with phenotypes where the genomic inflation factor was greater than 1.03 (GIF was calculated without SNPs where MAF is <0.05).
0	NA	NA	NA	METHODS	Conditional analyses on each of the genome-wide significant SNPs were conducted using the -condition function in PLINK.
0	Alzheimer's disease	NA	NA	METHODS	We also performed additional analyses in the genome-wide significant loci to determine the stability of the results when stratified by clinical AD status and by CSF AB42 levels.
0	NA	NA	NA	METHODS	CSF AB42 strata were based on levels that approximate amyloid deposition detected in PET scans using Pittsburgh Compound B (PIB).
0	NA	beta-amyloid (Abeta)	NA	METHODS	For the KADRC samples values less than 500 pg/ml indicate PIB retention/Abeta deposition, while values greater than 500 pg/ml indicate PIB negativity and the absence of Abeta deposition.
0	NA	beta-amyloid (Abeta)	NA	METHODS	For the ADNI samples values less than 192 pg/ml indicate retention/Abeta deposition, while values greater than 192 pg/ml indicate PIB negativity and the absence of Abeta deposition
0	NA	NA	NA	METHODS	We used the R package Multiphen, which performs a multivariate test of the linear combination of phenotypes most associated with the genotypes at each SNP, to evaluate each of the top hits for joint effects on multiple phenotypes in the study.
0	NA	NA	NA	METHODS	Analysis was carried out in the KADRC and ADNI samples separately using default settings as described here (http://cran.at.r-project.org/web/packages/MultiPhen/vignettes/MultiPhen.pdf)
0	NA	Interleukin 6 receptor	NA	METHODS	Initial results of IL6R indicated a GIF statistic greater than 1.03 suggesting the p-values were inflated by confounding variables.
0	NA	Interleukin 6 receptor	NA	METHODS	By removing a 500 kb window on either side of the strongest signal we identified that the inflation was due to the large number of highly significant p-values surrounding the IL6R gene (adjusted GIF = 1.017).
0	NA	NA	NA	METHODS	We did not remove this phenotype as it appears the inflation is due to a strong and replicable association signal in this single region.
0	NA	GIF	NA	METHODS	We analyzed other phenotypes that failed GIF quality control using the same strategy and did not observe similar phenomena
0	Alzheimer's disease	NA	NA	METHODS	For each locus where association was detected with the CSF endophenotypes we obtained data from the International Genomics of Alzheimer's Project (IGAP) association study of AD Stage 1 results.
0	NA	NA	NA	METHODS	IGAP is a large two-stage study based upon genome-wide association studies (GWAS) in individuals of European ancestry.
0	Alzheimer's disease	NA	NA	METHODS	In stage 1, IGAP used genotyped and imputed data for 7,055,881 single nucleotide polymorphisms (SNPs) to meta-analyse four previously-published GWAS datasets consisting of 17,008 Alzheimer's disease cases and 37,154 controls (The European Alzheimer's disease Initiative - EADI the Alzheimer Disease Genetics Consortium - ADGC The Cohorts for Heart and Aging Research in Genomic Epidemiology consortium - CHARGE The Genetic and Environmental Risk in AD consortium - GERAD).
0	Alzheimer's disease	NA	NA	METHODS	In stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of 8,572 Alzheimer's disease cases and 11,312 controls.
0	NA	NA	NA	METHODS	Finally, a meta-analysis was performed combining results from stages 1 & 2
0	NA	NA	NA	METHODS	We used ANNOVAR to annotate SNPs of interest with location and functional information.
0	NA	NA	NA	METHODS	RegulomeDB was used to annotate SNPs within known and predicted regulatory elements
0	NA	NA	NA	METHODS	We used SIFT and POLYPHEN2 for preliminary assessments of the functional consequences of amino acid changes
0	NA	NA	NA	METHODS	All data collection was conducted under approval by the appropriate Institutional Review Boards.
0	NA	NA	NA	METHODS	Analyses presented here were approved by the Institutional Review Board at Brigham Young University (E110252)
